Apoptosis as a tool for therapeutic agents in haematological diseases

被引：6
作者：
Alenzi, FQB
Wyse, RKH
Altamimi, WG
机构：
[1] King Faisal Univ, Coll Appl Med Sci, Dept Med Lab Sci, Dammam 31451, Saudi Arabia
[2] Univ London Imperial Coll Sci Technol & Med, Dept Cardiac Surg, London W12 0NN, England
[3] King Fahad Cent Hosp, Dept Pathol & Lab Med, King Abdulaziz Med City, Riyadh 11426, Saudi Arabia
来源：
EXPERT OPINION ON BIOLOGICAL THERAPY | 2004年 / 4卷 / 03期
关键词：
apoptosis; drug development; haematological disease; leukaemia; lymphoma;
D O I：
10.1517/14712598.4.3.407
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Apoptosis, an active mechanism of cell death, is an important process in many biological systems. Apoptosis is thought to contribute to many disease processes. This notion has raised expectations that therapeutic opportunities will naturally follow once a better understanding of these processes has been achieved. The regulation of apoptosis in normal and malignant haematological diseases represents an important theraputic approach in the treatment of leukaemia and lymphoma. This review summarises recent developments in the clinical manipulation of apoptosis pathways in haematological therapy.
引用
收藏
页码：407 / 420
页数：14
相关论文
共 159 条
  • [1] AGLIETTA M, 1989, EXP HEMATOL, V17, P296
  • [2] THE SPECTRUM OF MOLECULAR ALTERATIONS IN THE EVOLUTION OF CHRONIC MYELOCYTIC-LEUKEMIA
    AHUJA, H
    BARELI, M
    ARLIN, Z
    ADVANI, S
    ALLEN, SL
    GOLDMAN, J
    SNYDER, D
    FOTI, A
    CLINE, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (06) : 2042 - 2047
  • [3] Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal
    Albrecht, T
    Schwab, R
    Henkes, M
    Peschel, C
    Huber, C
    Aulitzky, WE
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) : 501 - 507
  • [4] Cellular and molecular themes in apoptosis
    Alenzi, FQB
    Warrens, AN
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2003, 115 (15-16) : 563 - 574
  • [5] A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics
    Alenzi, FQB
    Marley, SB
    Lewis, JL
    Chandrashekran, A
    Warrens, AN
    Goldman, JM
    Gordon, MY
    [J]. EXPERIMENTAL HEMATOLOGY, 2002, 30 (12) : 1428 - 1435
  • [6] Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3
    Amarante-Mendes, GP
    Kim, CN
    Liu, L
    Huang, Y
    Perkins, CL
    Green, DR
    Bhalla, K
    [J]. BLOOD, 1998, 91 (05) : 1700 - 1705
  • [7] APOPTOSIS IN CHRONIC MYELOID-LEUKEMIA - NORMAL RESPONSES BY PROGENITOR CELLS TO GROWTH-FACTOR DEPRIVATION, X-IRRADIATION AND GLUCOCORTICOIDS
    AMOS, TAS
    LEWIS, JL
    GRAND, FH
    GOODING, RP
    GOLDMAN, JM
    GORDON, MY
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) : 387 - 393
  • [8] Death receptors: Signaling and modulation
    Ashkenazi, A
    Dixit, VM
    [J]. SCIENCE, 1998, 281 (5381) : 1305 - 1308
  • [9] BEDI A, 1994, BLOOD, V83, P2038
  • [10] BCR-ABL-MEDIATED INHIBITION OF APOPTOSIS WITH DELAY OF G2/M TRANSITION AFTER DNA-DAMAGE - A MECHANISM OF RESISTANCE TO MULTIPLE ANTICANCER AGENTS
    BEDI, A
    BARBER, JP
    BEDI, GC
    ELDEIRY, WS
    SIDRANSKY, D
    VALA, MS
    AKHTAR, AJ
    HILTON, J
    JONES, RJ
    [J]. BLOOD, 1995, 86 (03) : 1148 - 1158
12345678910